Key takeaways
- β15% lower risk of death from any cause in high-risk patients
- β23% lower risk of heart attack confirmed across 50 trials
- βOverall serious adverse events also reduced by 7%
Quick specs
| Journal | BMC medicine |
| Year | 2025 |
| PMID | 41286875 |
What This Study Looked At
Researchers analyzed 50 clinical trials involving nearly 55,000 participants to understand both the benefits and side effects of semaglutide (the active ingredient in Ozempic and Wegovy) in people at higher risk of heart problems.Who Was Studied
The participants included people with:- Type 2 diabetes
- Overweight or obesity
- Type 2 diabetes plus chronic kidney disease
- Type 2 diabetes plus overweight
The Good News
Semaglutide showed meaningful protective effects:- 15% reduction in risk of death from any cause
- 23% reduction in risk of heart attack
- 7% reduction in serious adverse events overall
The Side Effects
On the downside, semaglutide significantly increased digestive side effects:- Nausea: 3 times more likely compared to placebo
- Vomiting: Over 4 times more likely
- Diarrhea: Nearly twice as likely
What This Means for You
If you are at increased risk of cardiovascular events and your doctor has recommended semaglutide, this large review strongly supports its ability to protect your heart and reduce your risk of dying. The digestive side effects are real and common, but they are generally manageable and considered non-serious medically. Always discuss your individual risk-benefit balance with your healthcare team.Frequently asked questions
Studies show semaglutide significantly increases the risk of nausea, vomiting, and diarrhea. These side effects are common but are considered non-serious and often improve over time as your body adjusts to the medication.
Editorial note
This article is for educational purposes only and does not constitute medical advice. Always consult your healthcare provider before making changes to your diabetes management. Last reviewed: July 16, 2026 by the MDS Diabetes editorial team.
What to do next
Topics
semaglutidecardiovascular riskheart attackside effectsGLP-1type 2 diabetesobesityresearch
